|
SYRE Spyre Therapeutics Inc 1636282 |
| Income Statement |
|
Net Income
|
2026-06-30
|
$-36,200,000.00 |
| Balance Sheet |
|
Current Assets
|
$1,173,003,000.00 |
|
Assets
|
$1,173,003,000.00 |
|
Current Liabilities
|
$63,302,000.00 |
|
Liabilities
|
$71,862,000.00 |
|
Equity
|
$1,101,141,000.00 |
|
Shares Out
|
88064133.00 |
| Cash Flow Statement |
|
Operating Cash Flow
|
$-127,249,000.00 |
|
Investing Cash Flow
|
$-241,323,000.00 |
| Market Analysis |
Market Cap
|
$9,492,432,896.07 |
|
Price
|
$107.79 |
|
BVPS
|
12.50 |
|
PB
|
8.62 |
|
EPS
|
-1.36 |
|
FCF
|
$-127,249,000.00 |
|
| Dividends |
|
Dividend Data Last Updated
|
2026-09-01 09:32:20 |
|
|
| Earnings |
|
Earnings Last Updated
|
2026-09-14 10:01:12 |
|
| Jan |
Feb |
Mar |
|
|
|
|
2026-02-19 |
-0.70 |
|
| Apr |
May |
Jun |
|
|
|
|
2026-05-05 |
-0.74 |
|
| Jul |
Aug |
Sep |
|
|
|
|
2025-08-05 |
-0.49 |
|
| Oct |
Nov |
Dec |
|
|
|
|
2025-11-04 |
-0.15 |
|
|
Find a discrepancy? The most accurate way to find company fundamental data is to view SYRE documents filed with the SEC.
SYRE Filings
Clear
